Please Wait...

Klause Engelke

Translation skills

Main profile

Klaus Engelke, PhD.
Director of Special Imaging Techniques

Professor Klaus Engelke received a Ph.D. in Physics from the University of Hamburg, Germany for his pioneering work on µCT using Synchrotron Radiation. Afterwards he joined the Osteoporosis Research Group at UCSF (University of California at San Francisco) to develop advanced radiographic methods for the diagnosis of osteoporosis. At UCSF he also developed the first workstation for vertebral fracture analysis using digitized x-rays. He then joined the newly formed Institute of Medical Physics (IMP) at the University of Erlangen, Germany to develop desktop µCT Scanners and advanced image processing methods. Prof. Engelke joined Synarc, now Bioclinica, as a Director of Special Imaging Techniques in 2005. At the University of Erlangen he continues to develop novel in vivo and in vitro image acquisition and analysis techniques for the musculoskeletal field. He has authored more than 100 peer reviewed publications and more than 200 conference contributions. In 2007 he chaired the QCT Task Force that developed the official positions of the International Society of Clinical Densitometry (ISCD) and is member of the committee that developed the German guidelines for the diagnosis and treatment of osteoporosis. In 2017 he was awarded the Dr. John P. Bilezikian Global Leadership Award from the International Society for Clinical Densitometry, which recognizes Klaus for his contributions to the advancement of osteoporosis and bone imaging research. He is also a member of the scientific advisory committee of the International Osteoporosis Foundation and co-chaired the Committee on Bone Densitometry of the International Commission on Radiation Units (ICRU).

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

ICYMI: Catch up on FDA Draft Guidance on BP Response in clinical trials https://t.co/uJp90qqQJx https://t.co/2dNI4AvXYU
Bioclinica (21 hours ago)
RT @Xtalks: Detection and Monitoring in #FattyLiver #ClinicalTrials: The Role of Medical Imaging NASH is characterized by the presence of a…
Bioclinica (22 hours ago)
RT @FCR_News_Today: CROs Deliver Shorter Cycle Times, Says New Tufts Report. #ClinicalTrial #ClinicalResearch https://t.co/PWe7qIGewt @…
Bioclinica (3 days ago)
RT @EMA_News: Today we are saying ‘hallo’ to our new home. Thank you, #Amsterdam and the Netherlands, for the warm welcome! https://t.co/hi…
Bioclinica (3 days ago)
RT @ACROhealth: How are patients finding #clinicaltrials? @Microsoft thinks chat bots could be the next recruitment frontier: #medtech #cli…
Bioclinica (3 days ago)
Join us in an upcoming webinar & learn how non-invasive imaging is being used in clinical trials to grade and monit… https://t.co/utvPe8UbPG
Bioclinica (3 days ago)

Latest Blogs:

Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box